> ## Content Index > Fetch the complete content index at: https://www.verolyx.org/llms.txt > Use this file to discover other available public pages before exploring further. # Medical Gloves - Disruption Risk Intelligence, Edition 5 - URL: https://www.verolyx.org/medical-gloves-disruption-risk-intelligence-edition-5/ - Published: 2026-10-01T12:32:49.000Z - Updated: 2026-10-01T13:24:43.000Z - Description: The global medical glove market is in surplus, yet health workers fighting Ebola in DRC ran short of gloves and PPE. Edition 5 examines nitrile glove supply chains, US tariffs, trade flows, and last-mile logistics, and why commodity data missed the frontline gap. - Author: Michael Griffin - Tags: critical care equipment supply chain vulnerability, Global Health Security, healthcare supply chain disruption prediction, disruption-intelligence, medical gloves, PPE, Ebola, Trade and Tariffs, DRC, Risk Intelligence, supply-chain-risk, Supply Chain Risk Intelligence VEROLYX Cross-Sector Disruption Intelligence Medical Gloves Disruption Risk Intelligence – Edition 5 1 October 2026 | 1 | At a Glance | ELEVATED | | - | ----------- | -------- | The world is not short of medical gloves. Eastern DRC’s Ebola front line was. Global producers ran below capacity throughout the Bundibugyo Ebola emergency, exports fell in 2025, and tariffs rerouted trade without removing supply. Yet from May to July 2026, health workers and aid agencies repeatedly reported running out of gloves and other PPE. The market never registered this emergency; the front line did. This edition tracks that gap, which commodity data alone cannot see. KEY TREND INDICATORS | DEMAND TRIGGER | Bundibugyo Ebola PHEIC, DRC (declared 17 May 2026): 8,116 confirmed cases and 3,924 deaths as of 27 September; second-largest Ebola outbreak on record | | ---------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | What is happening | Global glove supply is in surplus: producers run at 70–80% utilisation and the main exporters shipped 6% less by value in 2025 than in 2024\. At the same time, field reporting from May–July documented PPE shortages in Ituri, and 155 health workers had been infected by 9 August, mostly outside designated Ebola treatment centres. | | Why it matters beyond gloves | Any commodity can be abundant globally and absent locally. Market indicators (prices, utilisation, trade volumes) would have scored gloves as low-risk during a PHEIC with documented glove gaps. Risk monitoring that stops at the factory gate misses the failure that matters to patients and health workers. | | What to watch next | Whether PPE gaps persist outside treatment centres as the outbreak reaches new provinces; whether export prices, still rising through July, normalise in Q3 as producers forecast; and whether the new US forced-labour duties apply to gloves. | | 2 | Type of Risk | Demand Trigger | | - | ------------ | -------------- | Medical gloves’ taxonomy classification is a Demand Trigger: an epidemiological event, the Bundibugyo Ebola PHEIC, raises demand for a protective commodity whose production base is shared with health facilities around the world, food handling, industry and cleanroom manufacturing. It is not a Supply Shock Trigger (no event has damaged glove production or its feedstock), not a Structural Scarcity Trigger (capacity exceeds demand and production is spread across several countries), and not a Natural Disaster Trigger. This period, the Demand Trigger is too small to move the global market. By our order-of-magnitude estimate, the entire response consumes roughly 0.02–0.15% of annual global glove demand. The tier is carried instead by a gap between global supply and point-of-care availability: gloves existed, but did not reliably reach the facilities that needed them. See Sections 3 and 5. | 3 | Market Evidence | Value Chain Overview | | - | --------------- | -------------------- | Butadiene and acrylonitrile are polymerised into nitrile (NBR) latex, which is dipped into gloves on high-speed lines concentrated in Malaysia, China, Thailand and Indonesia. Commercial gloves move through distributors to hospitals worldwide. Humanitarian gloves follow a second path: UN long-term agreements and prepositioned stock in hubs such as Dubai, Copenhagen, Panama and Nairobi, and finally the last stretch to health zones. In 2026 the upstream chain was in surplus; the constraint sat at the far end of the humanitarian path. 1\. CROSS-SECTOR DEMAND LAYER - **Scale:** Global demand is about 330 billion pieces in 2026, against roughly 290 billion in 2019 (Hartalega estimate). Reported exports from the main producers totalled US$4.85bn in 2025, down 6% by value and 8% by weight from 2024 (UN Comtrade). - **Shared inputs:** NBR latex competes for butadiene with tyres and synthetic rubber. Its price rose from about US$0.70/kg in January to US$1.60/kg in May 2026 on Middle East conflict costs, with a \~38% easing expected in H2 (analyst estimates). - **Competing end-uses:** Food handling, industrial and cleanroom gloves run on the same producers’ lines; cleanroom demand from semiconductors and data centres is growing (Kossan targets 800m pieces of cleanroom capacity by FY2027). **Assessment:** *Healthcare shares feedstock and capacity with industry, but in 2026 that competition showed up in cost, not volume. Nobody was outbid for gloves.* 2\. VALUE CHAIN VULNERABILITY LAYER - **Producer concentration:** Malaysia holds about 50% of reported global export value, China 26% and Thailand 17% (2025). Utilisation of 70–80% leaves room to absorb shocks (industry survey, September 2026). - **The last mile:** On 4 June the Logistics Cluster reported strong incoming volumes of medical supplies, with storage needs linked to incoming pipeline "rather than immediate shortages". Facilities reported the opposite: only 7–34% had adequate IPC/WASH coverage in mid-May, and clinics lacked "gloves, protective gowns, masks" (ACAPS; KFF Health News). - **Commercially invisible:** DRC’s recorded glove imports from the main producers were about US$0.9m in 2025\. Humanitarian supply largely sits outside trade statistics. **Assessment:** *Two chains, two states: a commercial chain in surplus, and a humanitarian chain whose binding constraint was distribution from hub to facility, not production.* 3\. TRIGGER LAYER WHO declared the Bundibugyo Ebola outbreak in DRC and Uganda a PHEIC on 17 May 2026\. By 27 September, DRC had reported 8,116 confirmed cases and 3,924 deaths (CFR \~48%) in 63 of 167 health zones across seven provinces. There is no licensed vaccine or treatment specific to Bundibugyo virus, which makes infection prevention and control, and therefore gloves, the primary protection for health workers. WHO counted 155 health-worker infections and 45 deaths by 9 August, concentrated outside designated treatment centres. Historical precedent: health-worker infections linked to IPC gaps were a defining feature of the 2014–2016 West Africa outbreak. Neither that event nor this one registered in global glove supply. By late September, WHO described human resources as "one of the biggest gaps", which suggests the frontline constraint is shifting from supplies to staff. **Assessment:** *Severe outbreak, small footprint on the glove market. Its effect runs through the clinic, not the factory.* 4\. COMPETITIVE / STRUCTURAL LAYER US Section 301 duties on Chinese medical gloves rose to 50% in January 2025 and 100% in January 2026\. China’s share of US imports collapsed from 39% (2024) to 2% (2025), with the drop visible from the first month of the 50% rate (USITC). China did not leave the market: its exports to the US fell from US$533m to US$78m while exports to the EU rose from US$531m to US$607m. Malaysia and Thailand moved the other way, from Europe to the US (UN Comtrade). Prices, not volumes, are the live variable. Malaysian export unit values rose about 31% between September 2025 and July 2026, and Malaysian gas tariffs rise \~40% from October; producers nevertheless forecast normalisation from Q3\. Since 24 July, new US forced-labour duties (10% Malaysia, 12.5% China, Vietnam and Thailand) replace earlier tariffs; their application to gloves is unconfirmed. **Assessment:** *Tariffs produced a trade swap, not a supply shock. China rerouted to Europe and Southeast Asia rerouted to the US; global availability held.* | 4 | Composite Instability Scoring | | | - | ----------------------------- | | *Each tracked material or product receives a composite instability score built from five independently scored dimensions. The composite is not a precise probability estimate, but a structured, comparable severity read, intended to make several concurrent signals easy to compare at a glance.* | Dimension | Severity | Trend | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | **Signal Trajectory:**Is the underlying signal accelerating, steady, or resolving?*(Pulls from Trigger Layer)* | LOWMEDIUMHIGHHigh score signifies an escalating, unresolved trigger. | Outbreak still spreading geographically (seven provinces, new zones in September) but national incidence easing; market price pressure near its peak. | | **Concentration Risk:**How few independent points of failure exist, i.e. single country, single company, single product, etc.*(Pulls from Value Chain Vulnerability)* | LOWMEDIUMHIGHHigh score signifies lack of diversification. | About 93% of reported exports come from three countries, and delivery into Ituri depends on one airbridge and a few insecure road corridors. | | **Substitutability:**Does an alternative realistically exist? Is the alternative constrained?*(Pulls from Value Chain Vulnerability)* | LOWMEDIUMHIGHHigh score signifies constrained or unavailable substitutes. | Globally, many suppliers and latex/nitrile alternatives are available. At the point of care there is no substitute when stock is absent. | | **Time to Impact:**How much lead-time buffer exists before the disruption reaches an end user?*(Pulls from Trigger Layer and Value Chain Vulnerability)* | LONGTERMINTERMEDIATETERMIMMEDIATEImmediate signifies minimal buffer. | Prepositioned stock in hubs such as Dubai, Copenhagen and Nairobi covered the initial response, but PPE and IPC gaps were documented at facility level within weeks (ACAPS, 22 May). The buffer existed upstream but was thin at the point of care. | | **Precedent Frequency:**Has this pattern occurred before, and how often? Is it historically a one-off event versus a recurring event, market weakness?*(Pulls from Trigger Layer's historical record)* | LOWMEDIUMHIGHHigh signifies recurring precedents. | Facility-level IPC gaps and health-worker infections recur across filovirus responses, including West Africa 2014–2016. | *Composite is analyst-assigned against methodology's rubric, using public data. Not an automated statistical model.* | 5 | Final Assessment | ELEVATED | | - | ---------------- | -------- | This period’s ELEVATED classification is carried by the gap between global supply and point-of-care availability, not by the glove market. On market indicators alone, gloves would score at Monitoring: surplus capacity, falling export volumes and a trade swap that kept supply flowing. Event severity is very high, and documented PPE gaps in May–July amount to Active Disruption at facility level in parts of Ituri. Elevated reflects confirmed but localised impact on availability, with evidence that is real but not yet quantified. KEY TAKEAWAYS - The market never saw this emergency; the front line did. Producer data, trade flows and utilisation would have rated gloves low-risk during a PHEIC with documented glove and PPE gaps. That blind spot is the case for pairing commodity signals with operational ones. - This is a trade swap, not a supply shock: US tariffs pushed Chinese gloves into Europe and Southeast Asian gloves into the US, while global supply held. Price is the market variable to watch; export prices were still rising in July. - Whether gloves reach health workers is decided by prepositioned stock, funded last-mile logistics and staffing, not by global supply contracts. With funding now scaling (international commitments reported above US$2bn), the constraint is moving toward people and distribution. | A | Annex | Notes | | - | ----- | ----- | - Frontline evidence is qualitative and dated May–July 2026 (CARE, KFF Health News, NPR, ACAPS, WHO). No source quantifies glove stock-outs, consumption or the causal split between funding, insecurity and transport. September reporting points to staffing as the main gap. - Gloves may not have been the tightest PPE item. UNICEF Supply Division awarded no glove tenders in May–July but made an emergency procurement of Category III protective coveralls (US$1.01m, July 2026). The award does not name the outbreak, so the link is plausible, not documented. - The outbreak consumption estimate (\~49–490 million gloves, 0.02–0.15% of annual demand) is a Verolyx order-of-magnitude calculation with deliberately generous assumptions: admissions three times confirmed cases, 10-day stays, 200 gloves per patient-day, and a tenfold multiplier for wider IPC. - Data limits: global demand (330bn) and utilisation are company or analyst estimates. Comtrade lacks monthly data for China and Viet Nam, Malaysian weight data covers three months, and UAE (Dubai hub) data stops at 2023\. Whether the forced-labour duties apply to HTS 4015 is unconfirmed. Figures reflect research as of 1 October 2026 and should be refreshed each edition. | B | Annex | Sources | | - | ----- | ------- | *WHO Disease Outbreak News DON602, DON615, DON618 (May–Sep 2026); ECDC Ebola outbreak page (INSP data to 27 Sep 2026); CDC Ebola situation summary (23 Sep 2026); PBS/AP (24 Sep 2026, WHO on human-resources gap); ACAPS DRC Ebola briefing (22 May 2026); KFF Health News (5 Jun 2026); CARE (4 Jun 2026); NPR (30 Jun 2026); Al Jazeera (24 Jul 2026); PMC, IPC vulnerabilities in the 2026 Bundibugyo outbreak; Logistics Cluster, Ebola global call minutes (4 Jun 2026); UNICEF Supply Division contract awards (May–Jul 2026); UNICEF and EU supply releases (May 2026); MSF response page; Nairametrics and G20 pledge reporting (Sep 2026); WHO, Health worker Ebola infections in Guinea, Liberia and Sierra Leone (2015); Hartalega Q1 FY2027 quarterly report and AGM commentary; Top Glove 3QFY2026 results and briefing; Kossan 2QFY2026 Bursa filing; The Edge Malaysia, The Star, Business Today (Jun–Sep 2026 analyst coverage: TA Securities, PublicInvest, Maybank, Phillip Capital, CGS, MBSB, Kenanga); USTR Section 301 final action, 89 FR 76581 (Sep 2024); Holland & Knight, Baker Donelson (Jul 2026, Section 301 forced-labour duties); Global Trade Alert (IEEPA to Section 122); USITC DataWeb, HTS 4015.12 imports for consumption (Jan 2022–Jul 2026); UN Comtrade, HS 401512 exports (annual 2022–2025; monthly Sep 2025–Jul 2026; UAE re-exports 2022–2023).*